Deutsche Bank analyst James Shin maintains $Eli Lilly and Co (LLY.US)$ with a buy rating, and adjusts the target price from $1,025 to $1,015.
According to TipRanks data, the analyst has a success rate of 42.9% and a total average return of -6.5% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Eli Lilly and Co (LLY.US)$'s main analysts recently are as follows:
The firm acknowledges that after Eli Lilly's third-quarter earnings report, there may be heightened scrutiny on Zepbound scripts and inventory levels. Nonetheless, the sentiment is that the demand for GLP1 remains robust. Eli Lilly is considered to maintain the most compelling growth narrative amongst large-cap U.S. biopharmaceutical companies.
Eli Lilly's recent quarter showed uneven results for Mounjaro and Zepbound, which were attributed to inventory dynamics rather than supply or demand factors. Despite a temporary setback in the third quarter, the outlook on Lilly remains favorable, though estimates for Mounjaro and Zepbound have been slightly reduced.
Following the Q3 report, the potential for Eli Lilly to meet expectations has become more challenging due to the $1B shortfall in tirzepatide sales, necessitating significant efforts in Q4. This comes as channel inventories experience fluctuations and the push for direct-to-consumer efforts is delayed into later in the quarter.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
